Molecular Analysis of Samples From Patients With Diffuse Intrinsic Pontine Glioma and Brainstem Glioma
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01106794|
Recruitment Status : Recruiting
First Posted : April 20, 2010
Last Update Posted : November 8, 2021
|Condition or disease|
|Diffuse Intrinsic Pontine Glioma Brainstem Glioma|
|Study Type :||Observational|
|Estimated Enrollment :||100 participants|
|Official Title:||Molecular Analysis of Samples From Patients With Diffuse Intrinsic Pontine Glioma and Brainstem Glioma|
|Actual Study Start Date :||April 2010|
|Estimated Primary Completion Date :||April 2025|
|Estimated Study Completion Date :||April 2030|
Fresh-frozen and fixed tumor samples, correspondent normal brain tissue samples, cerebrospinal fluid, urine, and serum samples from patients affected with diffuse intrinsic pontine glioma or brainstem glioma
- Genome-wide expression patterns of RNA in tumor samples, normal brainstem tissue and cerebrospinal fluid using Affymetrix gene expression profiling [ Time Frame: 5 years ]Collected tumor and normal samples will potentially be used for RNA genome-wide expression pattern profiling.
- Validation of results of the genome-wide analysis [ Time Frame: 5 years ]The molecular analysis done on collected samples will be validated through whole genome sequencing.
- Proteomic profiling of tumor, normal brainstem tissue and cerebrospinal fluid [ Time Frame: 5 years ]To obtain full characterization of collected samples, proteomic profiling will be done on tumor and normal samples collected.
- Protein expression patterns as assessed by immunohistochemistry and western blot compared to normal brainstem tissue [ Time Frame: 5 years ]Collected tumor and normal samples will have the immunochemistry and western blot compared to assess protein expression variation.
- Genome-wide analysis of tumor samples and normal brainstem tissue [ Time Frame: 5 years ]To obtain full characterization of collected samples, whole genome sequencing will be done on tumor and normal samples collected.
- In vitro and in vivo molecular analysis of collected samples [ Time Frame: 5 years ]Collected samples will potentially be used for in vitro analysis and generation of animal models of this tumor.
- Assess aspects associated with specimen acquisition, including potential benefits and drawbacks [ Time Frame: 5 years ]In an effort to continue to draw knowledge from samples collected, potential benefits and drawbacks from specimen acquisition will be continuously accessed.
Biospecimen Retention: Samples With DNA
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01106794
|Contact: Javad Nazarian, PhD||202-476-6022||JNazarian@cnmc.org|
|Contact: Madhuri Kambhampati, MSemail@example.com|
|United States, District of Columbia|
|Children's National Medical Center||Recruiting|
|Washington, District of Columbia, United States, 20010|
|Principal Investigator: Javad Nazarian, PhD|
|Sub-Investigator: Roger Packer, MD|
|Sub-Investigator: Suresh Magge, MD|
|Sub-Investigator: Amanda L Muhs, MD|
|Principal Investigator:||Javad Nazarian, PhD||Children's National Research Institute|